WW
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Financial indicators Supports a bullish reading. Current ratio 1.69 · operating margin 6.5%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 7 235 titres (~100 132,40 $ US)
- Insiders
- Sjoqvist Nikolaj H
- Total bought
-
$100,132
Avg buy (VWAP, 90d window) $13.84 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | Sjoqvist Nikolaj H | Buy | 7,235 | $13.84 | $100,132 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-22
WW shows a genuine 2025 financial turnaround with improved liquidity (score 70) and recovering fundamentals (score 65), but the catalyst signal is weak: a single ~$100k insider buy with only 0.55 confidence, against a…
The first sentence of the analysis written for WW on 2026-08-22 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.8% | 67.8% | 59.5% | 59.8% | 60.0% | |
| Ebit Margin | 162.5% | -30.1% | 2.5% | -27.5% | 13.6% | |
| Ebitda Margin | 172.0% | -25.2% | 8.4% | -23.3% | 17.6% | |
| Operating Profit Margin | 6.5% | 10.0% | 2.9% | -27.3% | 16.2% | |
| Pretax Profit Margin | 153.6% | -43.9% | -8.3% | -35.3% | 6.4% | |
| Continuous Operations Profit Margin | 148.6% | -44.0% | -12.6% | -24.7% | 5.5% | |
| Net Profit Margin | 148.6% | -44.0% | -12.6% | -24.7% | 5.5% | |
| Bottom Line Profit Margin | 148.6% | -44.0% | -12.6% | -24.7% | 5.5% | |
| Current Ratio | 1.688 | 0.592 | 0.874 | 1.431 | 1.183 | |
| Quick Ratio | 1.688 | 0.592 | 0.873 | 1.327 | 1.050 | |
| Solvency Ratio | 1.787 | -0.185 | -0.034 | -0.124 | 0.061 | |
| Cash Ratio | 1.267 | 0.306 | 0.532 | 0.907 | 0.671 | |
| Price To Earnings Ratio | 0.276 | -0.295 | -5.993 | -1.078 | 16.802 | |
| Price To Earnings Growth Ratio | -0.002 | -0.001 | 0.101 | 0.002 | -1.243 | |
| Forward Price To Earnings Growth Ratio | -0.002 | -0.001 | 0.101 | 0.002 | -1.243 | |
| Price To Earnings Diluted Ratio | 0.276 | -0.295 | -5.993 | -1.078 | 16.979 | |
| Price To Earnings Diluted Growth Ratio | -0.002 | -0.001 | 0.101 | 0.002 | -1.514 | |
| Price To Book Ratio | 0.918 | -0.091 | -0.882 | -0.396 | -2.461 | |
| Price To Sales Ratio | 0.411 | 0.130 | 0.754 | 0.261 | 0.927 | |
| Price To Free Cash Flow Ratio | -6.295 | -3.063 | -22.655 | 7.070 | 9.390 | |
| Price To Operating Cash Flow Ratio | -10.104 | -6.049 | 100.347 | 3.541 | 7.142 | |
| Debt To Assets Ratio | 0.495 | 2.695 | 1.517 | 1.467 | 1.061 | |
| Debt To Equity Ratio | 1.473 | -1.331 | -1.957 | -2.199 | -3.323 | |
| Debt To Capital Ratio | 0.596 | 4.022 | 2.045 | 1.834 | 1.431 | |
| Long Term Debt To Capital Ratio | 0.594 | 4.523 | 2.144 | 1.931 | 1.475 | |
| Financial Leverage Ratio | 2.977 | -0.494 | -1.290 | -1.500 | -3.131 | |
| Working Capital Turnover Ratio | 86.743 | -16.260 | 30.265 | 16.399 | 2,136.093 | |
| Operating Cash Flow Ratio | -0.228 | -0.097 | 0.033 | 0.390 | 0.686 | |
| Operating Cash Flow Sales Ratio | -0.041 | -0.021 | 0.008 | 0.074 | 0.130 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.605 | 1.974 | -4.429 | 0.501 | 0.761 | |
| Debt Service Coverage Ratio | 18.722 | -1.826 | 0.377 | -1.626 | 2.316 | |
| Interest Coverage Ratio | 0.732 | 0.723 | 0.271 | -3.500 | 2.236 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.062 | -0.011 | 0.004 | 0.051 | 0.104 | |
| Capital Expenditure Coverage Ratio | -1.653 | -1.026 | 0.184 | 2.004 | 4.177 | |
| Dividend Paid And Capex Coverage Ratio | -1.653 | -1.026 | 0.184 | 2.004 | 4.177 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.491 | -7.720 | 27.446 | -6.621 | 11.648 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.8% | ▲4.0% | ▲8.1% |
| Ebit Margin | 162.5% | ▲192.6% | ▲138.3% |
| Ebitda Margin | 172.0% | ▲197.3% | ▲142.1% |
| Operating Profit Margin | 6.5% | ▼-3.5% | ▲4.9% |
| Pretax Profit Margin | 153.6% | ▲197.5% | ▲139.1% |
| Continuous Operations Profit Margin | 148.6% | ▲192.6% | ▲134.0% |
| Net Profit Margin | 148.6% | ▲192.6% | ▲134.0% |
| Bottom Line Profit Margin | 148.6% | ▲192.6% | ▲134.0% |
| Current Ratio | 1.688 | ▲1.096 | ▲0.534 |
| Quick Ratio | 1.688 | ▲1.096 | ▲0.582 |
| Solvency Ratio | 1.787 | ▲1.972 | ▲1.486 |
| Cash Ratio | 1.267 | ▲0.961 | ▲0.530 |
| Price To Earnings Ratio | 0.277 | ▲0.571 | ▼-1.666 |
| Price To Earnings Growth Ratio | -0.002 | ▼-0.001 | ▲0.227 |
| Forward Price To Earnings Growth Ratio | -0.002 | ▼-0.001 | ▲0.227 |
| Price To Earnings Diluted Ratio | 0.277 | ▲0.571 | ▼-1.701 |
| Price To Earnings Diluted Growth Ratio | -0.002 | ▼-0.001 | ▲0.281 |
| Price To Book Ratio | 0.918 | ▲1.009 | ▲1.500 |
| Price To Sales Ratio | 0.411 | ▲0.281 | ▼-0.086 |
| Price To Free Cash Flow Ratio | -6.295 | ▼-3.232 | ▼-3.185 |
| Price To Operating Cash Flow Ratio | -10.104 | ▼-4.055 | ▼-29.079 |
| Debt To Assets Ratio | 0.495 | ▼-2.200 | ▼-0.952 |
| Debt To Equity Ratio | 1.473 | ▲2.804 | ▲2.941 |
| Debt To Capital Ratio | 0.596 | ▼-3.426 | ▼-1.390 |
| Long Term Debt To Capital Ratio | 0.594 | ▼-3.929 | ▼-1.539 |
| Financial Leverage Ratio | 2.977 | ▲3.470 | ▲3.664 |
| Working Capital Turnover Ratio | 86.743 | ▲103.002 | ▼-363.906 |
| Operating Cash Flow Ratio | -0.228 | ▼-0.131 | ▼-0.385 |
| Operating Cash Flow Sales Ratio | -0.041 | ▼-0.019 | ▼-0.070 |
| Free Cash Flow Operating Cash Flow Ratio | 1.605 | ▼-0.369 | ▲1.523 |
| Debt Service Coverage Ratio | 18.722 | ▲20.548 | ▲15.130 |
| Interest Coverage Ratio | 0.732 | ▲0.009 | ▲0.640 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -0.062 | ▼-0.050 | ▼-0.079 |
| Capital Expenditure Coverage Ratio | -1.653 | ▼-0.627 | ▼-2.390 |
| Dividend Paid And Capex Coverage Ratio | -1.653 | ▼-0.627 | ▼-2.390 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.491 | ▲8.211 | ▼-4.558 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $292.0M | $101.9M | $670.9M | $271.4M | $1.12B | |
| Enterprise value | $600.3M | $1.53B | $2.05B | $1.60B | $2.49B | |
| EV / Sales | 0.84x | 1.95x | 2.31x | 1.54x | 2.05x | |
| EV / Op. cash flow | -20.77x | -90.97x | 306.77x | 20.89x | 15.81x | |
| EV / Free cash flow | -12.94x | -46.07x | -69.26x | 41.71x | 20.78x | |
| EV / EBITDA | 0.49x | -7.72x | 27.45x | -6.62x | 11.65x | |
| Net debt / EBITDA | 0.25x | -7.21x | 18.47x | -5.50x | 6.38x | |
| Current ratio | 1.69x | 0.59x | 0.87x | 1.43x | 1.18x | |
| Income quality | -0.03x | 0.05x | -0.06x | -0.30x | 2.34x | |
| Graham number | $275 | — | — | — | — | |
| Graham net-net | -$46 | -$2K | -$2K | -$2K | -$2K | |
| Tax burden | 96.8% | 100.2% | 152.5% | 70.0% | 87.2% | |
| Interest burden | 94.5% | 146.1% | -330.8% | 128.4% | 46.7% | |
| Working capital | $87.1M | -$70.7M | -$26.0M | $84.8M | $42.0M | |
| Invested capital | $788.9M | $342.5M | $739.2M | $794.7M | $1.17B | |
| Return on assets | 111.5% | -62.8% | -11.4% | -25.0% | 4.7% | |
| Operating ROA | 6.2% | 10.3% | 2.6% | -23.1% | 13.5% | |
| Return on tangible assets | 412.6% | -177.3% | -38.9% | -60.8% | 15.8% | |
| Return on equity | 332.0% | 31.0% | 14.7% | 37.5% | -14.7% | |
| Return on invested capital | 5.5% | 20.5% | 3.3% | -23.4% | 14.1% | |
| Return on capital employed | 5.7% | 20.9% | 3.3% | -34.1% | 16.4% | |
| Earnings yield | 361.7% | -339.4% | -16.7% | -94.6% | 6.0% | |
| Free cash flow yield | -15.9% | -32.6% | -4.4% | 14.1% | 10.6% | |
| Capex / Op. cash flow | -60.5% | -97.4% | 542.9% | 49.9% | 23.9% | |
| Capex / Depreciation | 25.8% | 43.4% | 69.2% | 87.3% | 77.6% | |
| Capex / Sales | 2.5% | 2.1% | 4.1% | 3.7% | 3.1% | |
| SG&A / Sales | 59.3% | 52.4% | 51.3% | 48.9% | 43.8% | |
| R&D / Sales | 6.0% | 5.4% | 5.3% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.7% | 1.0% | 1.7% | 1.2% | 1.8% | |
| Intangibles / Total assets | 73.0% | 64.6% | 70.6% | 58.9% | 70.2% | |
| Days sales outstanding | 8d | 7d | 6d | 9d | 9d | |
| Days payables outstanding | 17d | 26d | 19d | 16d | 17d | |
| Operating cycle | 8d | 7d | 6d | 26d | 32d | |
| Cash conversion cycle | -8d | -19d | -13d | 10d | 15d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-11-12 | Greg Gianforte | Sale (Partial) | $100,001 - $250,000 |
| 2020-03-02 | Greg Gianforte | Purchase | $15,001 - $50,000 |
| 2019-05-14 | Greg Gianforte | Purchase | $15,001 - $50,000 |
| 2019-05-13 | Greg Gianforte | Purchase | $15,001 - $50,000 |
Recent news
- 2026-08-07 What Prediction Markets Say About 3 Struggling Brands Fighting to Survive Polymarket and Kalshi traders have stayed completely silent on three struggling consumer brands facing serious balance sheet pressure, and that silence turns out to be one of the most revealing signals of all.
- 2026-08-06 WW International, Inc. (WW) Q2 2026 Earnings Call Transcript WW International, Inc. (WW) Q2 2026 Earnings Call Transcript
- 2026-08-06 WW International Q2 Earnings Call Highlights WW International (NASDAQ: WW), the parent company of Weight Watchers, reported second-quarter 2026 revenue of $162.3 million, down from $189.2 million a year earlier, while highlighting growth in its clinical and higher-value behavioral membership tiers and reaffirming its full-year financial outlook. The company said its second-quarter performance reflected progress in a multiyear transformation toward a business
- 2026-08-06 WW International Q2 Earnings Call Highlights WW International NASDAQ: WW, the parent company of Weight Watchers, reported second-quarter 2026 revenue of $162.3 million, down from $189.2 million a year earlier, while highlighting growth in its clinical and higher-value behavioral membership tiers and reaffirming its full-year financial outlook.
- 2026-08-05 Weight Watchers Announces Second Quarter 2026 Results Total End of Period Subscribers of 2.5 million; End of Period Clinical Subscribers of 197 thousand, up 55.7% year-over-year Core+ End of Period Subscribers of 541 thousand, up 13.9% year-over-year, reflecting third consecutive quarter of sequential growth Revenue of $162.3 million; Clinical Subscription Revenue of $39.9 million, up 30.4% year-over-year Reaffirms Full Year 2026 Financial Guidance NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the second quarter of 2026 ended June 30, 20261 in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company''s Corporate Website. “We view 2026 as a year of focused transition for Weight Watchers, and our Q2 results reflect that work taking hold across the business,” said Jon Volkmann, Chief Operations Officer and member of the Company''s Interim Office of the Chief Executive.
- 2026-07-23 Weight Watchers Schedules Second Quarter 2026 Earnings Conference Call NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the second quarter 2026 ended June 30, 2026, after market close on Wednesday, August 5, 2026. Weight Watchers will host a conference call to discuss results at 5:00 p.m.
- 2026-07-09 Sam''s Club® and Weight Watchers® Collaborate to Expand Access to Affordable, Holistic Wellness Experiences for Members Sam''s Club Plus members may receive a complimentary three-month Weight Watchers Core membership, while all Sam''s Club members can save up to 50% on select Weight Watchers programs
- 2026-07-08 Weight Watchers and FlavCity Announce Collaboration Focused on Strength, Nutrition, and Community NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced a new summer collaboration with FlavCity, the fast-growing health and wellness brand known for bringing transparency, simplicity, and authenticity to everyday food choices. As Weight Watchers'' official protein collaborator of the summer, FlavCity will help power the brand''s focus on strength, nutrition, and community.
- 2026-06-30 Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program.
- 2026-06-22 Weight Watchers to Support the American Heart Association''s Healthy Living BEYOND Weight Study Weight Watchers helps members achieve lasting weight loss through medication, personalized nutrition, and community support. As part of its collaboration with the American Heart Association, Weight Watchers is supporting enrollment and engagement in a nationwide study examining real-world health experiences and long-term health outcomes of people living with excess weight across weight management treatment pathways. Weight Watchers helps members achieve lasting weight loss through medication, personalized nutrition, and community support. As part of its collaboration with the American Heart Association, Weight Watchers is supporting enrollment and engagement in a nationwide study examining real-world health experiences and long-term health outcomes of people living with excess weight across weight management treatment pathways.